GUTS logo

GUTS Fractyl Health, Inc.

NASDAQ · Biotechnology · Healthcare

$0.82
-0.14 (-14.16%)

Fractyl Health, Inc., a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. The company develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans. It develops Rejuva, a novel aden…

Market Cap: $10.88Mfractyl.com

Price

No data yet.

Social Signal Score

38
5d
—
30d
35
2 mentions
—
60d
38
5 mentions
—
90d
40
10 mentions
—
news: 10

Analyst Ratings

3 analysts
Buyconsensus
Strong Buy 0Buy 2Hold 1Sell 0Strong Sell 0
Avg price target$5+509.8%
Low $5Median $5High $5
Current Consensus

Revenue

$0.00
$0.00$24.0K$48.0K$72.0K
Mar 2020Sep 2026

Analyst Estimates

FY2025
$-19.30
$-22.38–$-15.44
4 analysts
FY2026
$-3.87
$-4.60–$-2.87
3 analysts
FY2027
$-4.83
$-5.98–$-4.09
3 analysts

Consensus estimates, not results. Via Financial Modeling Prep.

Company Profile

CEO
Harith Rajagopalan
Sector
Healthcare
Industry
Biotechnology
Employees
100
Beta
2.42
Country
US
Piotroski score
1 / 9 (Weak)
Altman Z-score
-15.78
fractyl.com